香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 截 至2025年6月30日止六個月之 中期業績公告 財務摘要 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） | | | | | 截 | | | 至6月30日止六個月 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 2025年 | | | | | | 2024年 | | | | 變 動（2） | | 人民幣百萬元 | | | | | | | 人民幣百萬元 | | | | | | | | （未 | （未 經 ...

Group 1 - The core viewpoint of the article highlights the overall poor performance of Hong Kong's biopharmaceutical stocks, with significant declines in major companies such as WuXi AppTec, Tigermed, and King’s Ray Biotech [1] - U.S. President Trump announced plans to reduce drug prices to 1/1400 to 1/1500 of current prices and to impose tariffs on pharmaceuticals, which could create volatility in the global pharmaceutical industry [1] - The Chinese biopharmaceutical sector faces both opportunities and challenges due to these developments, with potential short-term market fluctuations driven by uncertainty, particularly for businesses exposed to the U.S. market [1] Group 2 - In the long term, China's pharmaceutical industry may leverage its innovation and supply chain advantages to find new growth opportunities in the global pharmaceutical landscape, especially in areas like CDMO and internationalization of innovative drugs [1] - The article lists the latest prices and percentage changes for various biopharmaceutical stocks, indicating a general downward trend across the sector [1]

Core Viewpoint - Tiger Med's stock price has shown fluctuations, with a year-to-date increase of 23.82% and a recent decline over the past 20 days, indicating mixed market sentiment towards the company [1][2]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1]. - The main business segments include clinical trial services (49.91% of revenue), clinical trial technical services (48.13%), and other services (1.95%) [1]. Financial Performance - For the first quarter of 2025, Tiger Med reported a revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Structure - As of March 31, 2025, Tiger Med had 53,800 shareholders, an increase of 1.95% from the previous period. The top shareholders include various mutual funds and ETFs, with notable changes in holdings among major institutional investors [3].

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Core Viewpoint - Tiger Medical (3347.HK) experienced a significant intraday drop of 6.43% to HKD 49.5, following a reduction in shareholding by a major shareholder, Xingsheng Global Fund Management Co., Ltd. [1] Group 1 - Xingsheng Global Fund Management Co., Ltd. sold 345,400 shares at an average price of HKD 58.4519 per share, amounting to approximately HKD 20.19 million [1] - After the sale, Xingsheng's shareholding decreased from 7.02% to 6.73% [1]

Group 1 - The core point of the news is that Xingsheng Global Fund Management Co., Ltd. has reduced its stake in Tiger Medical (03347.HK) by selling 345,400 shares at an average price of HKD 58.4519 per share, amounting to approximately HKD 20.1893 million [1] - After the reduction, Xingsheng's total shareholding is now 8,292,315 shares, which represents a decrease in ownership percentage from 7.02% to 6.73% [1]

Group 1 - Hong Kong Stock Exchange data shows that on August 15, Xingsheng Global Fund Management Co., Ltd. reduced its holdings in Tiger Medical (03347.HK) by 345,400 shares at a price of HKD 58.4519 per share, totaling approximately HKD 20.1893 million [1] - After the reduction, the latest number of shares held is approximately 8.2923 million, representing a holding ratio of 6.73% [1] - As of August 19, 2025, Tiger Medical closed at HKD 52.9, down 8.08%, with a trading volume of 3.8003 million shares and a turnover of HKD 209 million [1] Group 2 - Tiger Medical has a market capitalization of HKD 7.086 billion, ranking 11th in the medical services II industry [1] - Key performance indicators for Tiger Medical compared to the industry average are as follows: - ROE: 1.92% vs. industry average -0.76%, ranking 28th [1] - Market capitalization: HKD 7.086 billion vs. industry average HKD 8.298 billion, ranking 11th [1] - Revenue: HKD 6.603 billion vs. industry average HKD 3.819 billion, ranking 7th [1] - Net profit margin: 6.78% vs. industry average -851.29%, ranking 23rd [1] - Gross margin: 33.95% vs. industry average 36.91%, ranking 25th [1] - Debt ratio: 16.07% vs. industry average 73.63%, ranking 8th [1]

Group 1 - Hong Kong Stock Exchange data shows that on August 15, Xingsheng Global Fund Management Co., Ltd. reduced its holdings in Tiger Medical (300347)(03347) by 34,540 shares at a price of HKD 58.4519 per share, totaling approximately HKD 20.1893 million [1] - After the reduction, the latest number of shares held is approximately 8.2923 million, with a new holding percentage of 6.73% [1]

Group 1 - The core point of the article is that Xingsheng Global Fund Management Co., Ltd. has reduced its stake in Tiger Medical (03347) by selling 345,400 shares at a price of HKD 58.4519 per share, totaling approximately HKD 20.1893 million [1] - After the reduction, the latest number of shares held by Xingsheng Global is approximately 8.2923 million shares, representing a holding percentage of 6.73% [1]

Market Overview - The Hong Kong stock market experienced a slight decline on August 19, with the Hang Seng Index falling by 0.21% to 25,122.90, the Hang Seng China Enterprises Index down by 0.30% to 9,006.23, and the Hang Seng Tech Index decreasing by 0.67% to 5,542.03, indicating a relatively stable overall sentiment [1][2]. Sector Performance - Major technology stocks mostly declined, with significant drops in the film and television sector, semiconductor stocks, Chinese brokerage firms, rare earth concept stocks, innovative pharmaceuticals, gold stocks, and brain-computer interface concept stocks. Notably, the live-streaming stock Dongfang Zhenxuan plummeted nearly 21% [2][3]. - The property management sector showed strength throughout the day, while consumer sectors such as restaurants and sports goods performed actively [2][3]. Individual Stock Movements - Major tech stocks like NetEase and Xiaomi fell by 1.2% and 1.23% respectively, while Meituan and JD.com also saw slight declines. Tencent and Kuaishou experienced minor increases [4][5]. - Semiconductor stocks faced significant declines, with SMIC and Hua Hong Semiconductor dropping over 3%. However, a report from Tianfeng Securities suggests a positive outlook for global semiconductor growth driven by AI by 2025 [5][6]. - The pharmaceutical outsourcing sector saw substantial losses, with Tigermed down over 8% and other companies like WuXi AppTec and Zai Lab also declining significantly [7][8]. - Chinese brokerage stocks fell, with Xingsheng International down over 6% and other major firms like China International Capital Corporation and Shenwan Hongyuan also experiencing declines. However, there are indications of improving liquidity in the securities market, which could benefit brokerage firms [8]. Gold and Precious Metals - Gold and precious metals stocks declined, with companies like Chifeng Jilong Gold and Lingbao Gold dropping over 3%. Market sentiment is influenced by expectations surrounding the Federal Reserve's policy direction and geopolitical developments [8][9]. Property Management and Consumer Sectors - The property management sector saw notable gains, with Wanwu Cloud rising over 7% and other firms like Zhengrong Service and Rongchuang Service also increasing by more than 5%. This is supported by government measures to stabilize the real estate market [9][10]. - The restaurant sector experienced significant gains, with Daoxiang Holdings up over 11% and other companies like Xiaocaiyuan and Haidilao also showing positive performance [11]. Capital Inflows - Southbound funds recorded a net inflow of 18.573 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 8.911 billion HKD and the Shenzhen-Hong Kong Stock Connect adding 9.662 billion HKD [14]. Market Sentiment - Huatai Securities noted that the Hong Kong stock index has been fluctuating but is on an upward trend, with increased volatility. The market is currently in a critical phase awaiting verification of significant domestic and international events, suggesting a window for position adjustments [16].